Development and evaluation of a new chart for subcutaneous insulin administration in acute care settings
## Contents

1 Use of standard medication charts in hospitals  

2 Method  
   2.1 Design  
   2.2 National Insulin Form Project Advisory Group  
   2.3 Heuristic analysis  
   2.4 Consultation  
   2.5 Piloting  
   2.6 Evaluation  

3 Results  
   3.1 Combined hospital data  
      Changes associated with use of the chart  
      Patient identification and blood glucose level documentation  
      Routine insulin prescriptions  
      Supplemental insulin prescriptions  
      Stat/phone insulin prescriptions  
      Subcutaneous sliding scale insulin prescriptions  
      Use of charts in hospitals  
      Blood glucose control  
      Insulin prescribing and administration  
   3.2 Individual hospitals  
      Blood glucose control  
      Insulin prescribing and administration  

4 Rationale and conclusion  
   4.1 Rationale for the adoption of the chart  
   4.2 Conclusions  

5 Recommendations  

6 Appendices  
   Appendix 1 NIFPAG members  
   Appendix 2 Participating hospitals
Use of standard medication charts in hospitals
Key points

• The Australian Commission on Safety and Quality in Health Care (the Commission), through its clinical safety networks, identified the need for a national standard insulin chart.

• The Commission was approached by several states and territories, and individual public and private hospitals, suggesting that blood glucose level (BGL) control in hospitals is a national safety and quality issue.

• The Commission piloted a series of insulin charts over the course of the project to develop a national subcutaneous insulin chart.

Standard medication charts are known to reduce error and harm associated with medication errors, including errors and harm involving the use of insulin, which is classified as a high-risk medicine.

The Commission was approached by several states and territories, and individual public and private hospitals, suggesting that BGL control in hospitals is a national safety and quality issue. Poor glycaemic control, inadequate glucose monitoring and hypoglycaemia occur commonly and can compromise the outcome of a patient’s illness or procedure. A well-designed national insulin and BGL monitoring chart should reduce the risk of error when prescribing insulin, and improve patient outcomes and professional practice.

The Commission, through its clinical safety networks, identified the need for a national standard insulin chart as part of the medication safety program.

Optimal use of insulin requires careful recording of BGLs. Patients in acute care hospitals are subject to unstable BGLs. This can be caused by changes to dietary intake or access to food, periods of fasting, stress due to infection or surgery and treatment with medicines like corticosteroids. Control of BGLs may require insulin, or increase a patient’s need for insulin.

Since 2008, the Commission has received requests to develop a national, standardised insulin chart that:

• Reduces the risk of harm to people with insulin needs in hospitals
• Assists junior and inexperienced prescribers and other clinicians.

A standard national subcutaneous insulin chart could reduce the opportunity for error associated with the prescribing and administering of insulin. This would be achieved through:

• Improved BGL recording
• The ability to readily access and review recorded BGL or insulin data
• Improved accuracy and legibility of this data
• The provision of safety alerts and management guidelines.

The Commission’s work in medication standardisation has developed, in part, from its responsibility for maintaining the National Inpatient Medication Chart (NIMC). When the Australian Health Ministers’ Advisory Council (AHMAC) recommended the NIMC for national use in late 2007, it was acknowledged that specialist charts would be required to supplement the NIMC. This is reflected on the front page of the NIMC, where an ‘additional chart’ section indicates to prescribers that patients may require additional charts.

The Commission piloted a series of insulin charts over the course of the national subcutaneous insulin chart project. The project was overseen by the National Insulin Form Pilot Advisory Group (Appendix 1).
This report highlights the work that has been done as part of the insulin chart project. Results from the initial pilot of the national insulin chart in 2015 suggested that design work and further piloting were required to improve the utility of the chart.

Section 2 of this report describes how the chart was developed.

Section 3 of this report focuses on the outcomes of a second phase of piloting in acute care hospitals in 2016 of the redesigned national subcutaneous insulin chart.

Section 4 describes the conclusions and rationale for the national chart, and Section 5 recommends associated work for optimal implementation of the chart.
Method
2 Method

Key points

- Development of a national insulin chart was based on the Queensland Department of Health hospital subcutaneous insulin chart.

- The national subcutaneous insulin chart brings together the essential information required to manage the glycaemic treatment of hospitalised patients, including people with diabetes.

- An expert group provided technical advice and oversight to the chart project. An updated insulin chart was piloted in six hospitals in Queensland, Victoria and the Australian Capital Territory. Data were collected at the hospitals at two points in time – before the introduction of the subcutaneous insulin chart (pre-audit), and on completion of the pilot phase (post-audit).

- Two phases of piloting informed the development of the national subcutaneous insulin chart, in 2015 and 2016. Results from piloting of an earlier version of the chart in 2015 led to redesign of some areas of the chart. This report describes results for the second pilot.

The national subcutaneous chart was based on the chart developed by the Queensland Department of Health. The chart was modified and improved through several iterations using expert group advice and review, heuristic analysis, consultation and hospital piloting.

The hospital pilot study hypothesised that the use of a standardised chart for recording BGLs, prescribing and administering subcutaneous insulin, when combined with planned education and implementation:

- Reduces opportunities for error in subcutaneous insulin prescribing and administration
- Does not result in inferior blood glucose control.

2.1 Design

The Queensland Health chart was the basis for the development of a national insulin chart.

In October 2014, the Commission appointed human factors experts at the School of Psychology, University of Queensland, to develop a subcutaneous insulin chart. Development of the chart incorporated best human factors practice, information from the previous pilot, and human factors expertise and experience with hospital medication charts.

The national subcutaneous insulin chart brings together essential patient information to facilitate the improved glycaemic management of hospitalised patients. Specifically, the national subcutaneous insulin chart is designed to:

- Link the prescribing of subcutaneous insulin with administration and recorded BGLs
- Provide forcing functions to reduce the use of non-standard abbreviations and non-standard dosing regimens
- Provide guidelines for action to be taken in the event of BGLs reaching levels that indicate that the medical officer should be alerted and action taken
- Prompt daily review and adjustment of insulin doses in response to BGLs.
2.2 National Insulin Form Project Advisory Group

An expert group was formed to provide technical advice and oversight to the chart project. The National Insulin Form Project Advisory Group (NIFPAG), met over the course of the project. The group provided advice to the Commission on the design of the chart, the pilot process and the evaluation of the data gathered during the pilot. NIFPAG membership is shown in Appendix 1.

2.3 Heuristic analysis

The University of Queensland developed a heuristic evaluation protocol specifically tailored for insulin forms.

Questions specific to the insulin chart were developed that focused on:

- General issues such as:
  - page layout
  - information layout
  - font
  - colour scheme
  - cognitive load
  - language
  - other

- Actions and alerts such as:
  - identification and demographics
  - BGL frequency and notification instructions
  - additional instructions
  - documenting the diet
  - documenting BGLs
  - responding to suboptimal BGLs
  - ordering routine insulin
  - ordering supplemental insulin and determining the dose to be administered
  - ordering stat/phone insulin
  - administering insulin and documentation
  - ceasing orders
  - general concerns.

2.4 Consultation

Stakeholders were asked to review the new insulin chart using the heuristic analysis method developed specifically for insulin charts. The expert group considered the results and comments received. Where appropriate, these were incorporated into the development of a chart for piloting in hospitals.

2.5 Piloting

The chart was piloted in six hospitals in Queensland, Victoria and the Australian Capital Territory (Appendix 2). Pilot sites were selected through a targeted call for expressions of interest. This second pilot concluded in May 2016 with a final version of the acute care chart expected to be available in 2017.

The pilot consisted of the following phases:

- A pre-implementation (baseline) audit of insulin prescribing and documentation using the national inpatient medication chart or local hospital insulin form, before education of staff
- Education of medical, nursing and pharmacy staff on the pilot subcutaneous insulin chart using educational materials provided by the Commission
- Introduction of the subcutaneous insulin chart in each facility
- Audit of the subcutaneous insulin chart four months after implementation.

The objectives of the pilot were to evaluate the impact of the chart on:

- The safety and quality of prescribing and administration of subcutaneous insulin in the adult inpatient setting of an acute care hospital
- Blood glucose control.

2.6 Evaluation

Data were collected at the hospitals at two points in time:

- Before the introduction of the subcutaneous insulin chart (pre-audit)
- After the chart was in use for four months (post-audit).

The evaluation measured the impact of introducing the pilot subcutaneous insulin chart on the safety and quality of insulin prescribing and administration, and on the documentation and management of BGLs in adult inpatients.

The pilot also included an online survey of the hospital’s implementation experience and an issues register.
Results
Key points

- Thirty-five improvements in the prescribing of insulin and the management of people with diabetes were associated with using the new chart.
- The chart improved blood glucose control and had direct patient benefit overall, although there were hospital-to-hospital variations.
- Patients were less likely to experience hyperglycaemia and hypoglycaemia when the new chart was used, compared to before the pilot began.
- The pilot hospitals showed improvements in the clarity of insulin prescriptions written for routine, stat/phone and supplemental insulin.
- Six areas of focus were identified after implementation of the new chart, and classified as administrative issues that did not affect patient safety.

The data from all pilot hospitals were combined in the analysis; data from individual hospitals were also reviewed for differences among healthcare settings. The charts of 379 patients prescribed insulin were audited; 201 inpatients during the pre-audit (n=413 charts) and 178 inpatients during the post-audit (n=213 charts).

3.1 Combined hospital data

Changes associated with use of the chart

The Commission analysed the data from the acute care hospital pilot of the new national subcutaneous insulin form. To help interpret the data, all baseline to post-audit changes that were statistically significant (p < 0.05) and could be categorised as either ‘improvements’ or ‘areas of focus’ were identified. The introduction of the new chart was associated with 35 improvements and six areas of focus.

A data point which showed generally positive changes after introduction of the chart was considered an improvement. Areas of focus are the data points where negative changes were observed. The measurements were grouped into five categories: patient identification and blood glucose level (BGL) documentation, routine insulin orders, supplemental insulin orders, stat/phone insulin orders, and sliding scale insulin orders.

Patient identification and blood glucose level documentation

The following improvements in the following areas of insulin prescribing were observed:

- The average number of charts per patient was reduced
- The number of times insulin forms were cross-referenced in the regular medications section of the NIMC increased
- The recording of BGLs on the same chart where insulin is prescribed increased
- More prescribers documented their required frequency and timing of BGL monitoring for the patients in their care
- The number of days that BGLs are recorded as requested increased
- The number of BGLs recorded as accurate data points on the BGL line graph increased
- The documentation of the number of times the medical officer was notified of hypoglycaemia increased
- The number of BGLs in the range of 4 to 12mmol/L range increased
- The prescribing of insulin on the NIMC decreased
- The prescribing of insulin on hospital-specific insulin forms decreased
- The number of supplemental insulin orders charted appropriately increased.

The pilot did not highlight issues with the patient identification and BGL documentation.
3 Results

Routine insulin prescriptions
The following improvements were observed in routine insulin ordering:
• The proportion of orders where route of administration was clear increased
• The proportion of orders where route of administration was unclear decreased
• The proportion of orders where frequency of administration was clear increased
• The proportion of orders where frequency of administration was unclear decreased
• The proportion of orders where prescriber name was clear increased
• The proportion of doses prescribed that were clear increased
• The proportion of doses prescribed that used unapproved abbreviations decreased
• The proportion of doses that were missing decreased.

The pilot highlighted the following areas that will require focus for future implementations of the chart:
• The proportion of orders where the prescriber had signed decreased
• The proportion of doses initialed as having been administered decreased
• The proportion of doses with administration time documented decreased.

Supplemental insulin prescriptions
The following improvements were observed in supplemental insulin ordering:
• The proportion of orders where route of administration was clear increased
• The proportion of orders where route of administration was unclear decreased
• The proportion of orders where frequency of administration was clear increased
• The proportion of orders where frequency of administration was unclear decreased
• The proportion of orders where prescriber name is clear increased
• The proportion of doses prescribed that use unapproved abbreviations decreased
• The proportion of doses with administration time documented increased.

The pilot highlighted the following areas that will require focus for future implementations of the chart:
• The proportion of doses initialed as having been administered decreased.

Stat/phone insulin prescriptions
The following improvements were observed in stat/phone insulin prescriptions:
• The proportion of orders where route of administration was clear increased
• The proportion of orders where route of administration was unclear decreased
• The proportion of orders where prescriber name was clear increased
• The proportion of doses prescribed that use unapproved abbreviations decreased.

The pilot highlighted the following areas that will require focus for future implementations of the chart:
• The proportion of doses initialed as having been administered decreased
• The proportion of doses with administration time documented decreased.

Subcutaneous sliding scale insulin prescriptions
The following improvements were observed in sliding scale insulin orders:
• The proportion of orders where route of administration is clear increased
• The proportion of orders where route of administration is unclear decreased
• The proportion of doses prescribed clearly increased
• The proportion of doses prescribed that use unapproved abbreviations decreased
• The proportion of doses initialed as having been administered increased
• The proportion of doses with administration time documented increased.

Prescribers were discouraged from using subcutaneous sliding scale insulin in a written alert on the pilot chart. However, the audit did not identify significant use of subcutaneous sliding scale insulin prescriptions during the pilot. This may reflect prescriber adherence to the alert.

Use of charts in hospitals
Figure 1 shows uptake of the subcutaneous insulin chart once introduced to hospitals. Hospitals made the transition from using the NIMC and hospital-specific insulin charts to record and monitor insulin administration and BGLs. The insulin chart also requests that healthcare provider staff cross-reference the NIMC.
Figure 1 Changes in the use of charts, all hospitals combined

<table>
<thead>
<tr>
<th>Changes in the use of charts, all hospitals combined</th>
<th>Pre-audit</th>
<th>Post-audit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pilot subcutaneous insulin chart (post-audit only)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospital-specific insulin form</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIMC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulin form cross-referenced in the regular medications section of the NIMC</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NIMC = national inpatient medication chart

All changes were statistically significant, p < 0.01.

Blood glucose control

Figure 2 outlines the improvements in glycaemia management before and after the chart was introduced.

Figure 2 Hypoglycaemia and hyperglycaemia management, all hospitals combined

BGLs in the hypoglycaemic range of <4 mmol/L
BGLs in the recommended range of 4–12 mmol/L
BGLs greater than 20 mmol/L
BGLs in the hyperglycaemic range of 12–20 mmol/L
BGLs recorded correctly
Days BGLs were recorded
Requested frequency of BGL monitoring in the chart
Using the same form for BGL recording and insulin prescribing

* = statistically significant, p < 0.01; BGL = blood glucose level
These improvements were likely to result in direct patient benefit – more readings were seen in the recommended range and fewer readings outside of this range. That is, following introduction of the new chart, patients were less likely to experience hyperglycaemia and hypoglycaemia.

The decrease in the number of BGLs recorded which were greater than 20 mmol/L did not reach statistical significance ($p = 0.05$). This could be because of low statistical power, where the magnitude of the improvement documented could still be clinically important (4.2% to 3.3%). It is worth noting that the magnitude of some of the positive changes were substantial. For example, the percentage of days on which BGLs were recorded as requested increased from 35% to 86% following introduction of the new chart (Figure 2).

**Insulin prescribing and administration**

Overall, the pilot hospitals showed improvements in the prescribing of insulin for several prescription types: routine insulin prescriptions, supplemental insulin prescriptions and subcutaneous sliding scale insulin prescriptions. Stat and phone insulin orders, however, performed less well when compared with baseline performance. Potential reasons for this are discussed in the next section.

There were six areas of focus in which post-pilot results showed lower compliance than at baseline. For example, in some cases, prescribers wrote insulin orders but did not add their signature as required to authorise the order.

Of these, the main issue that could adversely affect the safety of people with diabetes is the decrease in the ‘total insulin doses prescribed that are clear’ for stat/phone orders. It is possible this occurred because the section is reduced in size on the new chart, and permits fewer such orders to be recorded compared with some other charts. It is important to note that some of the hospitals in the pilot typically used phone orders for most or all their routine insulin prescriptions. The structure of the national subcutaneous insulin chart supports daily prescribing of insulin while minimising the phone/stat orders section.

A strategy was devised to help hospitals manage situations where the phone/stat order section was used more frequently than the chart allows. An update was provided to pilot hospitals in the form of a frequently asked question (FAQ) document.

When possible, the phone order should be written directly into the routine insulin orders section on the new chart. In circumstances where there was already a dose written in the relevant cell of the routine insulin orders section, the FAQs recommended crossing out the dose, and cross-referencing to the stat/phone orders section.

These recommendations were designed to:
- Prevent clinicians from running out of room in the stat/phone orders section
- Take advantage of the alignment of the routine insulin orders section with the BGL monitoring and administration record sections.

It is possible that this advice was not followed in every case, which could account for some of the unclear stat/phone prescriptions. It is worth noting that the number of ‘total insulin doses prescribed which are clear’ for routine insulin orders significantly improved after the introduction of the new chart (from 93.8% to 97.8%, $p < 0.01$; data not shown).

Another area that showed lower compliance following introduction of the new chart was ‘total insulin doses that are missing’. This measure indicates that a signature to confirm administration of a dose has not been added to the chart; it does not necessarily mean that a dose has not been administered. If doses were not being administered, an increase in episodes of hyperglycaemia would have been observed in pilot hospitals.

### 3.2 Individual hospitals

**Blood glucose control**

Overall, improvements in blood glucose control were seen when hospital data was analysed. However, there was variation across hospitals with BGL control not improving in some (Figures 3 and 4). Possible reasons for these results include the small sample sizes in some of the pilot hospitals and incomplete implementation of the chart in some of the pilot hospitals.
Insulin prescribing and administration

Generally, the proportion of ‘insulin orders that are clear’ improved for most types of prescriptions. One hospital improved the clarity of their sliding scale insulin orders from 55.5% to 100.0% (p < 0.01; data not shown).
Rationale and conclusion
Key points

• The chart is beneficial for people with diabetes in an acute care hospital.
• Training will help to reverse administrative errors identified in the pilot.
• The results support the hypothesis that using a standardised chart for prescribing and administering subcutaneous insulin and recording blood glucose levels, combined with planned implementation and education, reduces errors in subcutaneous insulin prescribing and administration and does not result in inferior blood glucose control.
• An extensive evaluation of chart structure and composition concluded that further changes to chart design would not result in significant safety improvements relating to insulin use.

4.1 Rationale for the adoption of the chart

The pilot project showed that the new national subcutaneous insulin chart is beneficial to patients that need their diabetes monitored and controlled in an acute care hospital.

Most of the improvements identified are associated with direct patient benefit. Better BGL control and clearer subcutaneous insulin prescribing were observed.

Administrative errors were observed during both phases of the pilot, and must be addressed when the chart is introduced to a hospital. Errors of this type are common when new tools are introduced, such as the national subcutaneous insulin chart. Their resolution requires systematic monitoring of the chart’s performance, continued education and positive reinforcement of practice change among clinicians.

4.2 Conclusions

The national subcutaneous insulin chart yields better outcomes than alternative charts with which it was compared. The results support the hypotheses that using a standardised chart for prescribing and administering subcutaneous insulin and recording BGLs, when combined with planned implementation and education:

• Reduces errors in subcutaneous insulin prescribing and administration
• Does not result in inferior blood glucose control.

Further design work would not be beneficial at this stage. Rather than modifying the design of the chart, those issues that remain should be addressed through effective change management processes and training. These include providing more explicit training to all chart users on the phone order procedures that are currently outlined only in the frequently asked questions document.

It is expected that the negative changes seen will decrease as the new chart becomes more commonplace and familiar to staff.

Because of space constraints on the printed chart, many instructions are not included and will thus require user training. The expert group felt that regardless of the improvements to the chart, user training is essential.
Recommendations
Based on the outcomes of the pilot and evaluation of the national subcutaneous insulin chart:

1. The national subcutaneous insulin chart is recommended for use in all hospitals unless the existing chart or charts can be demonstrated to be as effective.

2. Jurisdictions and private hospitals considering implementation of the national subcutaneous insulin chart should
   a) confirm the expected benefits of implementation against local workflows and requirements in lead sites
   b) establish a plan to monitor the performance of the national subcutaneous insulin chart as part of the organisation’s clinical governance processes.

3. The national subcutaneous insulin chart should be implemented as part of an education program that explains how the chart should be used. Local variation should be minimal because the chart was extensively tested, meaning any changes could reduce the positive impact on prescribing. Permitted variations should be specified clearly in the accompanying support materials.

4. Support materials should be developed by the Commission to assist hospitals that wish to implement the national insulin subcutaneous chart.

5. Hospitals should support effective local implementation of the national subcutaneous insulin chart by
   a) developing an implementation plan with key stakeholders in the institution
   b) undertaking a risk assessment of the new chart and associated workflow changes
   c) using the national subcutaneous insulin chart implementation material developed by the Commission for their communication and training.

6. The Commission should initiate a stewardship and governance program to support the national implementation of the national subcutaneous insulin chart.

7. An evaluation of the national subcutaneous insulin chart and national implementation should be conducted 18 months after it has been authorised, to assess its ongoing safety performance and utility.
Appendices
Appendix 1 NIFPAG members

The National Insulin Form Pilot Advisory group members:

- Dr Merryn Thomae, Mater Health Services (Chair)
- Professor Trisha Dunning, Barwon Health
- Dr Peter Donovan, Queensland Health
- Ms Glenda Gorrie, Victorian Department of Health and Human Services
- Ms Fiona McIver, Medication Services Queensland, Queensland Department of Health
- Prof Charles Mitchell, University of Queensland
- Dr Kerry Newlin, Agency for Clinical Innovation NSW
- A/Professor Glynis Ross, Royal Prince Alfred Hospital and Bankstown-Lidcombe Hospital.
Appendix 2 Participating hospitals

The following hospitals participated in the phase two (2016) insulin chart pilots:

- Mater Private Hospital, Brisbane, Queensland
- Warringal Private Hospital, Melbourne, Victoria
- Canberra Hospital, Australian Capital Territory
- Mercy Public Hospital Werribee, Victoria
- Canossa Private Hospital, Brisbane, Queensland
- Mater Adult Hospital, Brisbane, Queensland.

The following hospitals participated in phase one (2015) of the insulin chart pilot:

- Northeast Health Wangaratta, Victoria
- Peter MacCallum Cancer Centre, Melbourne, Victoria
- Sunshine Coast Private Hospital, Sunshine Coast, Queensland
- Monash Health, Melbourne, Victoria
- Fremantle Hospital, Western Australia
- Mater Misericordiae Hospital Mackay, Queensland
- Rockingham Hospital, Perth, Western Australia.